Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 14/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13979539 | 1.00 | CTSC (0.60) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| SCHEMBL12240914 | 1.00 | CTSC (0.60) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| SCHEMBL2712722 | 0.84 | CYP2C19 (0.59) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| SCHEMBL288244 | 0.84 | CYP2C19 (0.70) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| SCHEMBL43293 | 0.84 | CYP2C19 (0.70) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| SCHEMBL9943773 | 0.84 | CYP2C19 (0.59) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| SCHEMBL2712724 | 0.84 | CYP2C19 (0.59) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| SCHEMBL43292 | 0.84 | CYP2C19 (0.70) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| SCHEMBL12219567 | 0.83 | CTSC (0.57) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL7382497 | 0.82 | CYP2C19 (0.68) | CTSCCYP2C19RAB9ASLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| EP-0191298-A2 | 1,6 -Naphthyridin-2(1H) - ones useful as cardiotonics and preparation thereof | STERLING DRUG INC. (US) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | CTSC 671/4885CYP2C19 4548/4885RAB9A 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.